Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Price:
35.79 CNY
-1.84%
Market Closed
Updated:
May 18, 2024
EV/OCF
Enterprise Value to OCF
Enterprise Value to OCF
64.2
Current
30.6
Median
16.2
Industry
Higher
than median
Higher
than industry value
Enterprise Value to Operating Cash Flow (EV/OCF) ratio is a valuation multiple that measures the value of a company, debt included, to the operating cash flow it generates.
EV/OCF
=64.2
Enterprise Value
/
26.5B
Operating Cash Flow
412.2m
All Countries
| Market Cap | EV/OCF | ||||
|---|---|---|---|---|---|
| CN |
|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
|
27.5B CNY | 64.2 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -19 905 438.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
731.8B USD | 205.1 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 43.2 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 6 930.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
372.2B USD | 16.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
332.3B USD | 24.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
187.7B GBP | 247.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
189B CHF | 12.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.7B CHF | 15.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161.7B USD | 25.1 |
EV/OCF Forward Multiples
Forward EV/OCF multiple is a version of the EV/OCF ratio that uses forecasted operating cash flow for the EV/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/OCF
N/A
2-Years Forward
EV/OCF
N/A
3-Years Forward
EV/OCF
N/A
You don't have any saved screeners yet
